B cells: a rational target in alloantibody‐mediated solid organ transplantation rejection
- 14 September 2005
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 20 (1) , 48-54
Abstract
Abstract: Loss of allografts over time remains a barrier to achieving successful outcomes in solid organ transplantation. Although the role of donor‐specific alloantibody‐mediated mechanisms in hyperacute rejection is well known, research and management of early and late post‐transplant rejection have traditionally focused on T cell‐mediated mechanisms. However, available agents that affect T‐cell pathways have minimal impact on long‐term graft survival, suggesting that other effector mechanisms are involved. A growing body of evidence now supports a role for alloantibody‐mediated mechanisms in early and late graft rejection, which can significantly impact on long‐term graft survival. The important role of B cells in generating and perpetuating alloantibody production provides a rationale for B‐cell depletion therapy as an approach to prevent or reduce alloantibody formation before transplantation and to treat or prevent early and late alloantibody‐mediated rejection. The use of monoclonal antibodies that directly target B cells, in combination with standard alloantibody‐depleting therapies and/or immunosuppression, has been investigated in several small non‐controlled studies. Promising results suggest that this strategy warrants further investigation in larger controlled studies.Keywords
This publication has 37 references indexed in Scilit:
- Donor-Specific Antibodies in Allograft Rejection: Clinical and Experimental DataTransplantation, 2005
- Is B Cell Tolerance Essential for Transplantation Tolerance?Transplantation, 2005
- Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174American Journal of Transplantation, 2004
- Preconditioning regimen consisting of anti‐CD20 monoclonal antibody infusions, splenectomy and DFPP‐enabled non‐responders to undergo ABO‐incompatible kidney transplantationClinical Transplantation, 2004
- RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)Transplantation, 2003
- Maintenance of Serological Memory by Polyclonal Activation of Human Memory B CellsScience, 2002
- All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodiesTransplantation, 2002
- RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2Transplantation, 1998
- REDUCED HUMAN IgG ANTI-ATGAM ANTIBODY FORMATION IN RENAL TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL1,2Transplantation, 1995
- COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI-CD ANTIGEN ANALYSIS BY FLOW CYTOMETRYTransplantation, 1995